Medical Treatment of Metastatic Renal Cell Carcinoma

Abstract

Italian

Thirty five patients with metastatic RCC were observed over a 57 months period in our Division of Radiotherapy and Medical Oncology, and 30 are evaluable for this analysis. MPA was selected as primary treatment agent in 23 patients, VLB singly, in combination with MPA or in combination with CCNU was used in 1.4 and 2 patients. With MPA the TR rate was 3/23 (1 CR and 2 PR). Duration of response for the patient with CR was 6 months whereas for the patients with PR was 21 and 14 months respectively. 4 additional patients showed NC. With VLB-MPA the TR rate was 1/4 (1 PR). Duration of PR was 3 months. The median duration of survival for the 11 patients with CR, PR and NC was 14 months whereas for the 19 patients with NR was 7 months (p < 0.01). TES and TAM showed no or minimal activity as second treatment agents.

Get full access to this article

View all access options for this article.

References

Al-Sarraf

: The clinical trial of Tamoxifen in patients with advanced renal cell cancer. A Southwest Oncology Group Study. Proc. Am. Assoc. Cancer Res., ASCO, C-360, p. 378, 1979.

Bloom

H.J.G.

: Hormone-Induced and Spontaneous Regression of Metastatic Renal Cancer. Cancer, 5: 1066–1072, 1973.

Cukiers

Bronstein

Beurton

Vacante

C.J.

Pascal

Amiel

J.C.

Oroz

J.P.

: Results of Radical Surgery in Adults with Renal Cancer. J. Urol. Nephrol., 84(718): 515–526, 1978.

Hahn

R.G.

Temkin

N.R.

Savlov

E.D.

Perlia

Wampler

G.L.

Hortow

Marsh

Carbone

P.P.

: Phase II Study of Vinblastine, Methyl-CCNU and Medroxyprogesterone in advanced Renal Cell Cancer. Cancer Treat. Rep., 62: 1093–1095, 1978.

Ishmael

D.R.

Burpo

I.J.

Bottomley

R.H.

: Combined Therapy of Advanced Hypernephroma with Medroxyprogesterone, BCG, Adriamycin and Vincristine. Proc. Am. Assoc. Cancer Res., ASCO, C-403, p. 407, 1978.

Katakkar

S.B.

Franks

C.R.

: Chemohormonal Therapy for Metastatic Renal Cell Carcinoma with Adriamycin, Hydroxyurea, Vinblastine and Medroxyprogesterone Acetate. Cancer Treat. Rep., 62: 1379–1380, 1978.

Klugo

R.C.

Detmers

Stiles

R.E.

Tall

J.R.W.

Cern

J.G.C.

: Aggressive versus Conservative Management of Stage IV Renal Cell Carcinoma. J. Urol., 118: 244–250, 1977.

Mittelman

: The chemotherapy of advanced renal cell carcinoma. In chemotherapy of Urogenital Tumors, pp. 9–25, Ed. Kugelmass

I.N.

Springfield, Illinois, U.S.A., 1975.

Pannuti

Martoni

Cricca

: Pilot study of the treatment of renal clear-cell carcinoma by high doses of Medroxyprogesterone Acetate (MPA). ICRS Med. Sci., Cancer, 6(6): 177, 1978.

10.

Terenius

: Anti-oestrogen and breast cancer. Eur. J. Cancer, 7: 57–64, 1971.

11.

Wagle

D.G.

Murphy

G.P.

: Hormonal therapy in advanced renal cell carcinoma. Cancer, 28: 318, 1971.

12.

Wasserman

T.H.

Comis

R.L.

Goldsmith

: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother. Rep., Part 3, Vol. 6(2): 399–419, 1975.